Ann: Appendix 4E and Annual Report 30 June 2023, page-2

This is a sleeping giant.

$16m market cap and $21m cash

Phase III trials to commence in the next few months.

Their product TR Pro+ is already for sale and receiving positive feedback from clinics and patients. It has over an 85% customer satisfaction rate which is significant. Massive addressable market for wound healing and no decent topical product on the market.

This will rerate hard once phase III trials commence, it won’t take much for this to hit $100m market cap,

(advice for management - change the name of TR Pro+, it’s so lame and the average person can’t make sense of it. ChatGPT gave these cool names, HealGuard, EpiRepair, SwiftHeal)